|
|
| Line 1: |
Line 1: |
| [[Image:2nv3.jpg|left|200px]] | | {{Seed}} |
| | [[Image:2nv3.png|left|200px]] |
|
| |
|
| <!-- | | <!-- |
| Line 9: |
Line 10: |
| {{STRUCTURE_2nv3| PDB=2nv3 | SCENE= }} | | {{STRUCTURE_2nv3| PDB=2nv3 | SCENE= }} |
|
| |
|
| '''Solution structure of L8A mutant of HIV-1 myristoylated matrix protein'''
| | ===Solution structure of L8A mutant of HIV-1 myristoylated matrix protein=== |
|
| |
|
|
| |
|
| ==Overview==
| | <!-- |
| During the late phase of human immunodeficiency virus type-1 (HIV-1) replication, newly synthesized retroviral Gag proteins are targeted to lipid raft regions of specific cellular membranes, where they assemble and bud to form new virus particles. Gag binds preferentially to the plasma membrane (PM) of most hematopoietic cell types, a process mediated by interactions between the cellular PM marker phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P(2)) and Gag's N-terminally myristoylated matrix (MA) domain. We recently demonstrated that PI(4,5)P(2) binds to a conserved cleft on MA and promotes myristate exposure, suggesting a role as both a direct membrane anchor and myristyl switch trigger. Here we show that PI(4,5)P(2) is also capable of binding to MA proteins containing point mutations that inhibit membrane binding in vitro, and in vivo, including V7R, L8A and L8I. However, these mutants do not exhibit PI(4,5)P(2) or concentration-dependent myristate exposure. NMR studies of V7R and L8A MA reveal minor structural changes that appear to be responsible for stabilizing the myristate-sequestered (myr(s)) species and inhibiting exposure. Unexpectedly, the myristyl group of a revertant mutant with normal PM targeting properties (V7R,L21K) is also tightly sequestered and insensitive to PI(4,5)P(2) binding. This mutant binds PI(4,5)P(2) with twofold higher affinity compared with the native protein, suggesting a potential compensatory mechanism for membrane binding.
| | The line below this paragraph, {{ABSTRACT_PUBMED_17188710}}, adds the Publication Abstract to the page |
| | (as it appears on PubMed at http://www.pubmed.gov), where 17188710 is the PubMed ID number. |
| | --> |
| | {{ABSTRACT_PUBMED_17188710}} |
|
| |
|
| ==About this Structure== | | ==About this Structure== |
| 2NV3 is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2NV3 OCA]. | | 2NV3 is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2NV3 OCA]. |
|
| |
|
| ==Reference== | | ==Reference== |
| Line 33: |
Line 37: |
| [[Category: Tai, J.]] | | [[Category: Tai, J.]] |
| [[Category: L8a mutant of hiv-1 myristoylated matrix protein]] | | [[Category: L8a mutant of hiv-1 myristoylated matrix protein]] |
| ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 09:56:39 2008'' | | |
| | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 07:39:01 2008'' |
